# Ikena Oncology Inc. (IKNA)

Source: https://www.quantisnow.com/company/IKNA
Generated: 2026-11-19T07:01:48.313Z

- Ticker: IKNA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- Website: ikenaoncology.com

## About

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

## Latest IKNA news and filings

- 2025-08-01 20:59 UTC [SEC Form 8-K] [Ikena Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events](https://www.quantisnow.com/insight/ikena-oncology-inc-filed-sec-form-8-k-leadership-update-other-6143267)
- 2025-07-31 01:30 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Yarema Kristin](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-yarema-kristin-6139384)
- 2025-07-31 01:30 UTC [SEC Form 4] [Director Orbimed Advisors Llc was granted 83,611 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-orbimed-advisors-llc-was-granted-83611-shares-sec-form-6139382)
- 2025-07-31 01:28 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-ikena-oncology-inc-6139381)
- 2025-07-30 20:51 UTC [Insider Buy] [Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)](https://www.quantisnow.com/insight/director-bonita-david-p-converted-options-into-379-shares-and-6139098)
- 2025-07-30 20:47 UTC [Insider Buy] [Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)](https://www.quantisnow.com/insight/director-stampacchia-otello-converted-options-into-379-shares-and-bought-6139077)
- 2025-07-30 01:32 UTC [SEC Form 4] [Chief Financial Officer Marango Jotin was granted 15,776 shares and covered exercise/tax liability with 4,630 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-marango-jotin-was-granted-15776-shares-and-6137297)
- 2025-07-29 23:02 UTC [SEC Form 4] [Principal Accounting Officer Butler Erin was granted 3,051 shares (SEC Form 4)](https://www.quantisnow.com/insight/principal-accounting-officer-butler-erin-was-granted-3051-shares-sec-6137219)
- 2025-07-29 22:58 UTC [SEC Form 3] [SEC Form 3 filed by new insider Butler Erin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-butler-erin-6137208)
- 2025-07-29 22:56 UTC [SEC Form 3] [SEC Form 3 filed by new insider Yarema Kristin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-yarema-kristin-6137206)
- 2025-07-29 20:53 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-ikena-oncology-inc-6136862)
- 2025-07-29 10:04 UTC [SEC Form 8-K] [Ikena Oncology Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Leadership Update, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure](https://www.quantisnow.com/insight/ikena-oncology-inc-filed-sec-form-8-k-completion-of-acquisition-6135140)
- 2025-07-28 18:16 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-ikena-oncology-inc-6134202)
- 2025-07-25 16:23 UTC [SEC Form 8-K] [Ikena Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/ikena-oncology-inc-filed-sec-form-8-k-regulation-fd-disclosure-6132811)
- 2025-07-25 15:00 UTC [Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million](https://www.quantisnow.com/insight/inmagene-biopharmaceuticals-announces-completion-of-merger-with-ikena-oncology-and-6132773)
- 2025-07-24 21:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-ikena-oncology-inc-6132103)
- 2025-07-24 13:18 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ikena-oncology-inc-6131137)
- 2025-07-23 13:00 UTC [Leadership Update] [Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company](https://www.quantisnow.com/insight/ikena-oncology-and-inmagene-biopharmaceuticals-announce-kristin-yarema-phd-as-6129253)
- 2025-07-22 20:20 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ikena-oncology-inc-6128370)
- 2025-07-18 20:01 UTC [SEC Form D] [SEC Form D filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-ikena-oncology-inc-6125369)
- 2025-07-16 20:40 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ikena-oncology-inc-6122356)
- 2025-07-15 20:50 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ikena-oncology-inc-6120944)
- 2025-07-15 20:15 UTC [Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals](https://www.quantisnow.com/insight/ikena-oncology-announces-stockholder-approval-of-merger-with-inmagene-biopharmaceuticals-6120711)
- 2025-07-11 12:38 UTC [SEC Form 425] [SEC Form 425 filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-ikena-oncology-inc-6117642)
- 2025-07-11 12:34 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ikena-oncology-inc-6117638)
- 2025-07-11 12:00 UTC [Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene Biopharmaceuticals](https://www.quantisnow.com/insight/ikena-oncology-announces-iss-and-glass-lewis-recommend-stockholders-vote-6117523)
- 2025-07-01 20:18 UTC [SEC Form 425] [SEC Form 425 filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-ikena-oncology-inc-6106001)
- 2025-07-01 20:15 UTC [SEC Form 8-K] [Ikena Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/ikena-oncology-inc-filed-sec-form-8-k-regulation-fd-disclosure-6105961)
- 2025-06-19 00:23 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-ikena-oncology-inc-6092642)
- 2025-06-16 16:21 UTC [SEC Form SCHEDULE 13D filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13d-filed-by-ikena-oncology-inc-6087607)
- 2025-06-12 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-ikena-oncology-inc-6082952)
- 2025-06-11 21:08 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-ikena-oncology-inc-6082502)
- 2025-06-09 11:14 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-ikena-oncology-inc-6077543)
- 2025-05-30 20:47 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-ikena-oncology-inc-6065598)
- 2025-05-20 21:04 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-ikena-oncology-inc-6050801)
- 2025-05-08 12:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-ikena-oncology-inc-6026140)
- 2025-05-07 20:16 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-ikena-oncology-inc-6024322)
- 2025-04-21 20:42 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-ikena-oncology-inc-5994927)
- 2025-03-28 20:30 UTC [Leadership Update] [Traws Pharma Announces Management Updates](https://www.quantisnow.com/insight/traws-pharma-announces-management-updates-5965029)
- 2025-03-18 20:18 UTC [SEC Form S-4] [SEC Form S-4 filed by Ikena Oncology Inc.](https://www.quantisnow.com/insight/sec-form-s-4-filed-by-ikena-oncology-inc-5949873)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/IKNA
- Earnings history: https://www.quantisnow.com/earnings/IKNA
- Dividend history: https://www.quantisnow.com/dividends/IKNA
- Insider transactions: https://www.quantisnow.com/insiders/IKNA
- Options chain: https://www.quantisnow.com/options/IKNA
- SEC 8-K filings only: https://www.quantisnow.com/company/IKNA/8-k
- RSS and alerts for IKNA: https://www.quantisnow.com/docs/rss-feeds.md
